Active — Not RecruitingPhase 2

Phase ll Study of HEC585 in Patients With IPF

China270 participantsStarted 2021-06-30

Plain-language summary

A Phase ll Study to evaluate the efficacy and safety of various doses of HEC585 Tablets in patients with idiopathic pulmonary fibrosis

Age range40 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Any cytotoxic drug or immunosuppressant
✕. Therapeutic drugs for IPF, including but not limited to pirfenidone, nintedanib, prednisone at \> 15 mg/d or other glucocorticoids of the equivalent dose, N-acetylcysteine at \> 600 mg/d.
✕. Moderate and strong inhibitor or strong inducer of CYP1A2.
✕. Strong inducers or strong CYP3A4 inhibitors.

Change from Baseline to Week 24 in %FVC compared with placebo

Timeframe: 24 Weeks

NCT IDNCT05060822

SponsorSunshine Lake Pharma Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-07-16